Developing Photoaffinity Probes for Dopamine Receptor D 2 to Determine Targets of Parkinson's Disease Drugs

• Published in: ACS chemical neuroscience Vol. 13; no. 20; pp. 3008 - 3022
• Main Authors: Kim, Spencer T, Doukmak, Emma J, Flax, Raymond G, Gray, Dylan J, Zirimu, Victoria N, de Jong, Ebbing, Steinhardt, Rachel C
• Format: Journal Article
• Language: English
• Published: United States 19.10.2022
• Subjects: Animals; Carrier Proteins; Dopamine Agonists - pharmacology; Endocannabinoids; Ligands; Nitric Oxide Synthase Type I - metabolism; Parkinson Disease - drug therapy; Proteomics; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2 - metabolism; Receptors, GABA - metabolism; dopamine receptors; ropinirole; proteomics; pramipexole; bioinformatics; photoaffinity labeling (PAL); GABA receptor; muscarinic receptor M1; DRD2; photo-cross-linking; endocannabinoid pathway
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.2c00544

Dopaminergic pathways control highly consequential aspects of physiology and behavior. One of the most therapeutically important and best-studied receptors in these pathways is dopamine receptor D (DRD2). Unfortunately, DRD2 is challenging to study with traditional molecular biological techniques, and most drugs designed to target DRD2 are ligands for many other receptors. Here, we developed probes able to both covalently bind to DRD2 using photoaffinity labeling and provide a chemical handle for detection or affinity purification. These probes behaved like good DRD2 agonists in traditional biochemical assays and were able to perform in chemical-biological assays of cell and receptor labeling. Rat whole brain labeling and affinity enrichment using the probes permitted proteomic analysis of the probes' interacting proteins. Bioinformatic study of the hits revealed that the probes bound noncanonically targeted proteins in Parkinson's disease network as well as the retrograde endocannabinoid signaling, neuronal nitric oxide synthase, muscarinic acetylcholine receptor M1, GABA receptor, and dopamine receptor D (DRD1) signaling networks. Follow-up analysis may yield insights into how this pathway relates specifically to Parkinson's disease symptoms or provide new targets for treatments. This work reinforces the notion that the combination of chemical biology and omics-based approaches provides a broad picture of a molecule's "interactome" and may also give insight into the pleiotropy of effects observed for a drug or perhaps indicate new applications.